Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SARAH C JACKSON

Allopathic & Osteopathic Physicians Dermatology

NPI
1790724326
CMS profile
35319
Location
NEW ORLEANS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$33,153.83

143 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–143 of 143 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SARAH C JACKSON

NPI 1790724326 · CMS profile ID 35319

Allopathic & Osteopathic Physicians / Dermatology

NEW ORLEANS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–143 of 143 matching records. This page contains 43 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790724326?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SARAH C JACKSON, NPI 1790724326, CMS profile ID 35319. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–143 of 143 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790724326?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SARAH C JACKSON, NPI 1790724326, CMS profile ID 35319. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–143 of 143 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790724326?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SARAH C JACKSON, NPI 1790724326, CMS profile ID 35319, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–143 of 143 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1790724326?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

143 matching records · $33,153.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 143 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–143 of 143.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Galderma Laboratories, L.P. $18.2304/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952278411 CMS
ABBVIE INC. $21.6704/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892901905 CMS
ABBVIE INC. $3.9503/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892901901 CMS
ABBVIE INC. $3.4003/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892901897 CMS
Sun Pharmaceutical Industries Inc. $119.5403/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947906489 CMS
Allergan, Inc. $32.2603/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889912151 CMS
Allergan, Inc. $50.0003/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889912153 CMS
Allergan, Inc. $7,245.0003/24/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889912155 CMS
Allergan, Inc. $122.5303/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889912157 CMS
Sun Pharmaceutical Industries Inc. $13.0903/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947906497 CMS
ABBVIE INC. $0.3403/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892901885 CMS
ABBVIE INC. $13.7203/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892901889 CMS
ABBVIE INC. $14.6103/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892901893 CMS
MAYNE PHARMA INC. $21.5703/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959856809 CMS
LEO Pharma Inc. $13.2503/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936232365 CMS
Almirall LLC $16.7803/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902849185 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $15.5903/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947513365 CMS
ABBVIE INC. $25.6702/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892901877 CMS
ABBVIE INC. $13.6202/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892901881 CMS
Allergan, Inc. $15.2302/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889912149 CMS
GENZYME CORPORATION $24.8502/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938926389 CMS
LEO Pharma Inc. $17.5102/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936232361 CMS
Merz North America, Inc. $16.1902/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950345725 CMS
PFIZER INC. $15.3902/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949629235 CMS
LEO Pharma Inc. $17.0002/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936232357 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $3.3902/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947513361 CMS
Sun Pharmaceutical Industries Inc. $10.9702/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947906459 CMS
Sun Pharmaceutical Industries Inc. $4.0602/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947906453 CMS
LEO Pharma Inc. $14.2601/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936232353 CMS
MAYNE PHARMA INC. $2.9701/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959925457 CMS
Sun Pharmaceutical Industries Inc. $10.8001/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947906515 CMS
ABBVIE INC. $20.9301/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892901869 CMS
ABBVIE INC. $6.6601/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892901873 CMS
Allergan, Inc. $74.3301/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889912147 CMS
ABBVIE INC. $21.0701/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892901865 CMS
Allergan, Inc. $1,950.0001/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889912145 CMS
Galderma Laboratories, L.P. $12.1101/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952278409 CMS
MAYNE PHARMA INC. $10.9601/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959925485 CMS
PFIZER INC. $13.2201/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949054411 CMS
MAYNE PHARMA INC. $18.4301/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959925663 CMS
Galderma Laboratories, L.P. $3,575.0001/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952278405 CMS
Galderma Laboratories, L.P. $3,575.0001/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952278407 CMS
MAYNE PHARMA INC. $10.9601/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959925493 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $75,853.25 201
PY2020 $18,824.82 99
PY2021 $20,830.14 143
PY2022 $33,153.83 143
PY2023 $13,816.02 93
PY2024 $2,288.35 92
PY2025 $2,557.17 75

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $219,279.02 200
PY2024 Recipient $685.33 4
PY2024 Principal investigator $258,818.56 461
PY2023 Principal investigator $308,241.41 299
PY2022 Principal investigator $319,656.41 97
PY2021 Principal investigator $234,316.22 68
PY2020 Principal investigator $125,729.85 42
PY2019 Principal investigator $101,599.47 34

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

200 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $8,420.82 12/31/2025 Non-covered Recipient Entity
DELRICHT RESEARCH AT TOURO MEDICAL CENTER
A Prospective, Open-Label Study to Evaluate Subject Satisfaction with Overall Facial Appearance After Treatment with JUVeDERM Products in Medical Weight Loss (MWL) Subjects No dispute reported 06/30/2026 1202534503
Principal investigator 1 SANOFI PASTEUR INC. $8,673.80 12/22/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112742
Principal investigator 1 Incyte Corporation $2,252.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524792
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524850
Principal investigator 1 Incyte Corporation $2,112.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524865
Principal investigator 1 Incyte Corporation $2,112.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524870
Principal investigator 1 Incyte Corporation $1,810.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524878
Principal investigator 1 Incyte Corporation $1,810.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524883
Principal investigator 1 SANOFI PASTEUR INC. $500.00 12/16/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112727
Principal investigator 1 Incyte Corporation $500.00 12/10/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524795
Principal investigator 1 Incyte Corporation $30.00 12/05/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524802
Principal investigator 1 Incyte Corporation $966.00 12/05/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524833
Principal investigator 1 Incyte Corporation $500.00 12/05/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524854
Principal investigator 1 Incyte Corporation $67.00 12/05/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524861
Principal investigator 1 Incyte Corporation $43.00 12/05/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524955
Principal investigator 1 Incyte Corporation $1,104.00 12/04/2025 Non-covered Recipient Entity
DELRICHT CLINICAL RESEARCH LLC-CLINEDGE-PPDS
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240522695
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524799
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524805
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524809
Principal investigator 1 Incyte Corporation $23.70 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524813
Principal investigator 1 Incyte Corporation $23.70 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524818
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524822
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524825
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524858
Principal investigator 1 Incyte Corporation $0.34 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524913
Principal investigator 1 Incyte Corporation $18.96 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524918
Principal investigator 1 Incyte Corporation $49.77 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524934
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524942
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524946
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524959
Principal investigator 1 SANOFI PASTEUR INC. $159.60 11/26/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112482
Principal investigator 1 SANOFI PASTEUR INC. $14,522.80 11/25/2025 Non-covered Recipient Entity
Delricht Llc
A Phase 1/2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Participants With Mild Acne No dispute reported 06/30/2026 1226112870
Principal investigator 1 Incyte Corporation $169.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524837
Principal investigator 1 Incyte Corporation $169.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524841
Principal investigator 1 Incyte Corporation $1,088.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524874
Principal investigator 1 Incyte Corporation $3,280.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524890
Principal investigator 1 Incyte Corporation $3,280.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524894
Principal investigator 1 Incyte Corporation $3,280.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524899
Principal investigator 1 Incyte Corporation $3,280.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524904
Principal investigator 1 Incyte Corporation $3,280.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524907
Principal investigator 1 Incyte Corporation $2,252.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524910
Principal investigator 1 Incyte Corporation $53.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524938
Principal investigator 1 Incyte Corporation $186.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524963
Principal investigator 1 Incyte Corporation $266.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524966
Principal investigator 1 SANOFI PASTEUR INC. $3,982.86 11/14/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112825
Principal investigator 1 Incyte Corporation $2,206.00 11/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524923
Principal investigator 1 Incyte Corporation $100.00 11/07/2025 Non-covered Recipient Entity
DELRICHT CLINICAL RESEARCH LLC-CLINEDGE-PPDS
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240522693
Principal investigator 1 Incyte Corporation $1,500.00 11/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524829
Principal investigator 1 Incyte Corporation $100.00 11/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524846
Principal investigator 1 Incyte Corporation $5,000.00 11/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524886
Principal investigator 1 Incyte Corporation $2,000.00 11/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524926
Principal investigator 1 Incyte Corporation $2,500.00 11/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524930
Principal investigator 1 Incyte Corporation $10,000.00 11/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524951
Principal investigator 1 SANOFI PASTEUR INC. $15,469.34 10/31/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112494
Principal investigator 1 SANOFI PASTEUR INC. $5,548.98 10/16/2025 Non-covered Recipient Entity
Delricht Llc
A Phase 1/2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Participants With Mild Acne No dispute reported 06/30/2026 1226112853
Principal investigator 1 Incyte Corporation $293.00 10/09/2025 Non-covered Recipient Entity
DELRICHT CLINICAL RESEARCH LLC-CLINEDGE-PPDS
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240522684
Principal investigator 1 Incyte Corporation $259.00 10/09/2025 Non-covered Recipient Entity
DELRICHT CLINICAL RESEARCH LLC-CLINEDGE-PPDS
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240522689
Principal investigator 1 SANOFI PASTEUR INC. $31,252.47 10/09/2025 Non-covered Recipient Entity
Delricht Llc
A Phase 1/2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Participants With Mild Acne No dispute reported 06/30/2026 1226112789
Principal investigator 1 SANOFI PASTEUR INC. $300.00 10/09/2025 Non-covered Recipient Entity
Delricht Llc
A Phase 1/2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Participants With Mild Acne No dispute reported 06/30/2026 1226112793
Principal investigator 1 SANOFI PASTEUR INC. $300.00 10/02/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112762
Principal investigator 1 Incyte Corporation $300.00 09/17/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524780
Principal investigator 1 Incyte Corporation $259.00 09/04/2025 Non-covered Recipient Entity
DELRICHT CLINICAL RESEARCH LLC-CLINEDGE-PPDS
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240522677
Principal investigator 1 Incyte Corporation $293.00 09/04/2025 Non-covered Recipient Entity
DELRICHT CLINICAL RESEARCH LLC-CLINEDGE-PPDS
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240522681
Principal investigator 1 Incyte Corporation $43.00 08/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524756
Principal investigator 1 Incyte Corporation $30.00 08/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524761
Principal investigator 1 Incyte Corporation $1,560.00 08/01/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524776
Principal investigator 1 Incyte Corporation $50.00 07/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524768
Principal investigator 1 Incyte Corporation $100.00 07/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524772
Principal investigator 1 Incyte Corporation $2,524.00 07/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524784
Principal investigator 1 Incyte Corporation $43.00 07/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524765
Principal investigator 1 Incyte Corporation $43.00 07/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524788
Principal investigator 1 Incyte Corporation $342.00 06/25/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524578
Principal investigator 1 Incyte Corporation $2,524.00 06/25/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524580
Principal investigator 1 Incyte Corporation $50.00 06/23/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524672
Principal investigator 1 Incyte Corporation $43.00 06/13/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524585
Principal investigator 1 Incyte Corporation $1,560.00 06/11/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524676
Principal investigator 1 Incyte Corporation $1,560.00 06/11/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524680
Principal investigator 1 SANOFI PASTEUR INC. $300.00 06/09/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112692
Principal investigator 1 Incyte Corporation $300.00 06/04/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema No dispute reported 06/30/2026 1240524653
Principal investigator 1 Incyte Corporation $64.72 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524625
Principal investigator 1 Incyte Corporation $64.72 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524628
Principal investigator 1 Incyte Corporation $34.35 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524632
Principal investigator 1 Incyte Corporation $45.80 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524637
Principal investigator 1 Incyte Corporation $11.33 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524656
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524660
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524665
Principal investigator 1 Incyte Corporation $124.54 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524668
Principal investigator 1 Incyte Corporation $14.42 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524685
Principal investigator 1 Incyte Corporation $6.36 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524718
Principal investigator 1 Incyte Corporation $6.36 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524722
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524725
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524730
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524734
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524740
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524744
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524748
Principal investigator 1 SANOFI PASTEUR INC. $3,097.66 05/28/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112614
Principal investigator 1 Incyte Corporation $1,599.00 05/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524572
Principal investigator 1 Incyte Corporation $1,599.00 05/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524753
Principal investigator 1 SANOFI PASTEUR INC. $300.00 05/16/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112669
Principal investigator 1 Incyte Corporation $300.00 05/12/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524568
Principal investigator 1 Incyte Corporation $178.00 05/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema No dispute reported 06/30/2026 1240524564
Principal investigator 1 Incyte Corporation $1,808.00 05/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema No dispute reported 06/30/2026 1240524689
Principal investigator 1 SANOFI PASTEUR INC. $6,084.06 05/09/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112631
Principal investigator 1 Incyte Corporation $32.36 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524642
Principal investigator 1 Incyte Corporation $9.72 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524646
Principal investigator 1 Incyte Corporation $22.90 05/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524649
Principal investigator 1 Incyte Corporation $100.00 04/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524542
Principal investigator 1 Incyte Corporation $1,560.00 04/09/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524698
Principal investigator 1 Incyte Corporation $500.00 04/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524546
Principal investigator 1 Incyte Corporation $70.00 04/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524550
Principal investigator 1 Incyte Corporation $86.00 04/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524552
Principal investigator 1 Incyte Corporation $100.00 04/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524701
Principal investigator 1 Incyte Corporation $2,377.00 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524557
Principal investigator 1 Incyte Corporation $1,599.00 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524560
Principal investigator 1 Incyte Corporation $41.10 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524590
Principal investigator 1 Incyte Corporation $41.10 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524594
Principal investigator 1 Incyte Corporation $12.15 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524598
Principal investigator 1 Incyte Corporation $1.55 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524603
Principal investigator 1 Incyte Corporation $123.40 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524606
Principal investigator 1 Incyte Corporation $26.78 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524611
Principal investigator 1 Incyte Corporation $14.42 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524616
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524621
Principal investigator 1 Incyte Corporation $118.26 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524693
Principal investigator 1 Incyte Corporation $41.10 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524706
Principal investigator 1 Incyte Corporation $41.10 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524710
Principal investigator 1 Incyte Corporation $32.96 04/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524714
Principal investigator 1 SANOFI PASTEUR INC. $300.00 03/18/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112557
Principal investigator 1 Incyte Corporation $1,599.00 03/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524309
Principal investigator 1 Incyte Corporation $197.44 03/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524434
Principal investigator 1 Incyte Corporation $68.70 03/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524438
Principal investigator 1 Incyte Corporation $16.96 03/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524442
Principal investigator 1 Incyte Corporation $65.76 03/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524447
Principal investigator 1 Incyte Corporation $65.76 03/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524450
Principal investigator 1 Incyte Corporation $118.26 03/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524531
Principal investigator 1 Incyte Corporation $65.76 03/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524534
Principal investigator 1 Incyte Corporation $65.76 03/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524538
Principal investigator 1 SANOFI PASTEUR INC. $12,149.63 02/21/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112532
Principal investigator 1 SANOFI PASTEUR INC. $500.00 02/19/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112527
Principal investigator 1 Incyte Corporation $1,725.00 02/10/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524301
Principal investigator 1 Incyte Corporation $300.00 02/07/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema No dispute reported 06/30/2026 1240524289
Principal investigator 1 SANOFI PASTEUR INC. $9,535.98 02/03/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112517
Principal investigator 1 Incyte Corporation $2,377.00 01/27/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524296
Principal investigator 1 Incyte Corporation $40.00 01/24/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524293
Principal investigator 1 Incyte Corporation $43.00 01/24/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524470
Principal investigator 1 Incyte Corporation $1,690.00 01/15/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524264
Principal investigator 1 Incyte Corporation $1,736.00 01/15/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524268
Principal investigator 1 Incyte Corporation $50.00 01/15/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524279
Principal investigator 1 Incyte Corporation $1,670.00 01/15/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524455
Principal investigator 1 SANOFI PASTEUR INC. $300.00 01/09/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112521
Principal investigator 1 Incyte Corporation $266.00 01/08/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524274
Principal investigator 1 Incyte Corporation $30.00 01/08/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524283
Principal investigator 1 Incyte Corporation $43.00 01/08/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524466
Principal investigator 1 Incyte Corporation $90.10 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524304
Principal investigator 1 Incyte Corporation $254.40 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524313
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524317
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524321
Principal investigator 1 Incyte Corporation $74.20 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524326
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524330
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524334
Principal investigator 1 Incyte Corporation $32.28 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524338
Principal investigator 1 Incyte Corporation $84.80 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524341
Principal investigator 1 Incyte Corporation $84.80 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524346
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524350
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524354
Principal investigator 1 Incyte Corporation $12.15 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524358
Principal investigator 1 Incyte Corporation $91.60 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524362
Principal investigator 1 Incyte Corporation $1.55 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524366
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524370
Principal investigator 1 Incyte Corporation $123.40 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524374
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524379
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524382
Principal investigator 1 Incyte Corporation $21.20 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524386
Principal investigator 1 Incyte Corporation $82.20 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524390
Principal investigator 1 Incyte Corporation $16.18 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524393
Principal investigator 1 Incyte Corporation $4.86 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524398
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524402
Principal investigator 1 Incyte Corporation $246.80 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524406
Principal investigator 1 Incyte Corporation $137.40 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524410
Principal investigator 1 Incyte Corporation $21.20 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524414
Principal investigator 1 Incyte Corporation $82.20 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524417
Principal investigator 1 Incyte Corporation $80.90 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524421
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524424
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524428
Principal investigator 1 Incyte Corporation $8.48 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524432
Principal investigator 1 Incyte Corporation $41.20 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524459
Principal investigator 1 Incyte Corporation $135.40 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524463
Principal investigator 1 Incyte Corporation $82.20 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524474
Principal investigator 1 Incyte Corporation $82.20 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524479
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524483
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524487
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524492
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524496
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524499
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524504
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524509
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524513
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524517
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524522
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524526